Antibody-Drug conjugates (ADCs) are targeted anti-cancer drugs consisting of three parts:

Antibodies: Precisely recognize specific antigens on the surface of tumor cells (such as HER2, TROP2, etc.).

Linker: Maintains stability in the blood circulation and releases toxins within tumor cells.

Toxin (Payload) : Highly efficient in killing tumor cells (such as MMAE, DM1, etc.).

Through targeted delivery: antibodies bind to tumor cells → endocytosis into cells → linker breakage to release toxins → kill cancer cells, reduce damage to normal cells, and expand the treatment window.

CSBio can provide:

I. Core Raw Materials for ADC

Toxins (Payload) : MMAE, DM1, SN-38, etc. Custom synthesis is supported.

Linker: cleavable type (VC, VA), non-cleavable type (MC, MP).

Antibody engineering: Humanization modification, affinity optimization, site-specific conjugation modification.

Ii. ADC Development Services

Antibody screening and validation: High-throughput target evaluation, functional validation.

Process development: From small-scale trials to medium-scale trials (200L scale), yield > 85%.

Analysis and quality control: DAR detection, residual solvent analysis, forced degradation research.

Clinical application support: CMC data compilation, dual application in China and the United States (FDA/NMPA)

Click to view our antibody-drug conjugates